by Fred Dumais | Oct 1, 2024 | News Release
MONTREAL, QUEBEC, October 1, 2024,— Valeo Pharma Inc. (TSX: VPH, FSE: VP2), a Canadian pharmaceutical company, announced today that the Québec Superior Court (Commercial Division) (the “Court”) has issued an initial order (the “Initial Order”) granting the Company and...
by Fred Dumais | Sep 12, 2024 | News Release
Q3-24 revenues of $12.6 million, down 11% from Q3-23, excluding XIIDRA, growth trend from continued business remains healthy at +9%, Q3-24 vs Q3-23 Q3-24 adjusted EBITDA loss of $1.5 million compared to $2.5 million for Q3-23, down 40% MONTREAL, QUEBEC, September...
by Fred Dumais | Sep 9, 2024 | News Release
MONTREAL, QUEBEC , September 9, 2024 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2024...
by Fred Dumais | Sep 3, 2024 | News Release
MONTREAL, QUEBEC, September 3, 2024 – Valeo Pharma Inc. (TSX: VPH, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that it has entered into an agreement (the “Amendment”) with Sagard Healthcare Royalty Partners, LP...
by Fred Dumais | Aug 29, 2024 | News Release
MONTREAL, QUEBEC, August 29, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that the Company is voluntarily delisting its Class A shares from trading on the OTCQB Venture...
by Fred Dumais | Aug 6, 2024 | News Release
MONTREAL, QUEBEC, August 6, 2024 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, today announced that the Company’s Chief Development Officer, Mr. Al Moghaddam, has been appointed to succeed...
